(2020) demonstrated that the SERCA selective modulators JQ-FT and CAD204520, respectively, preferentially target cells harboring gain-of-function NOTCH1 mutations over WT in T-ALL (49, 50). The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.